{
  "docId": "019de073-8778-764b-accb-e5886cb9e840",
  "docSlug": "a27c0c380497fe380fc0ea99c606f1fe",
  "documentTitle": "Equillium | Results Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 32,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a 'Bench to Bedside' narrative structure to present scientific evidence.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-8778-764b-accb-e5886cb9e840/12",
  "deckHref": "/decks/019de073-8778-764b-accb-e5886cb9e840",
  "deckJsonHref": "/decks/019de073-8778-764b-accb-e5886cb9e840.json",
  "deckAnchorHref": "/decks/019de073-8778-764b-accb-e5886cb9e840#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.45,
        "y": 0.7
      },
      "kind": "chart",
      "text": "Urine ALCAM (pg/mg)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afcb094c-831e-47cf-bd44-236ba36d1192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.45,
        "y": 0.4
      },
      "kind": "chart",
      "text": "CD6 and ALCAM expression",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f577f58f-3eb8-412e-93d6-79929ffa8245",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "chart",
      "text": "MRL/lpr % Survival",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a53847af-3830-41a9-9508-2e529c3e5a57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.7,
        "y": 0.15
      },
      "kind": "image",
      "text": "JCI Journal cover illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f73bf12-086a-42fc-b4d8-6a3a1d199e19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Pre-clinical: Blockade of CD6 shown to be efficacious in multiple pre-clinical models of SLE/LN. Translational: Antigen specific, autoreactive CD6+ T cells key to SLE/LN pathogenesis; Single cell RNAseq data of LN kidneys versus normal showed 16x increase in infiltrating CD6+ T cells, 9x increase in ALCAM expression on renal tissues; Urinary ALCAM a biomarker of active disease. Clinical: Exploratory analysis of SLE patients in Type A portion of the EQUALISE study, with elevated UPCR & UACR, showed an improvement with treatment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80adb58b-dd7d-4452-abef-ad7ca1094025",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "UPCR, urine protein creatinine ratio; UACR, urine albumin creatinine ratio. 1. Chalmers et al., Journal of Clinical Investigation, 2022; 2. Abdirama et al., Clinical Investigation, 2021; 3. Parodis et al., Rheumatology, 2020; 4. Putterman et al., PO1624 ASN, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f050b99-9d85-45e6-b5d9-4ea31a1c6039",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Bench to Bedside: The CD6-ALCAM Pathway In Lupus Nephritis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a59e6491-9278-4062-bac3-288766c3aa33",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "239c0cd9-d41d-4ef1-9085-000a88bf1348",
      "evidence": "Bench to Bedside: The CD6-ALCAM Pathway In Lupus Nephritis",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "Bench to Bedside",
      "slug": null,
      "matchId": "d65e10b6-3ee3-467f-acf1-12ca86cecd46",
      "evidence": "The slide title and structure explicitly follow the bench-to-bedside research progression model.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 31,
      "from": 10,
      "beatId": "74c9ceff-f718-432a-b48e-9f41e627272b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Itolizumab's potential solution is presented, with efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f935949f-a063-4f53-ae76-c20f25bdff22",
      "evidence": "The presentation implies the cost of inaction through the unmet medical need and limitations of current treatments.",
      "position": 0,
      "objective": "What is the cost of not treating Lupus Nephritis effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5a9857ab-edc2-421f-aac9-92c4e50656db",
      "evidence": "The presentation discusses itolizumab's mechanism of action and efficacy in treating Lupus Nephritis.",
      "position": 1,
      "objective": "What are the jobs to be done in treating Lupus Nephritis?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}